A Phase 1, Open-Label, Multicenter, Dose Escalation And Expansion Study Of NKTR-214 In Subjects With Locally Advanced Or Metastatic Solid Tumor Malignancies

Trial Profile

A Phase 1, Open-Label, Multicenter, Dose Escalation And Expansion Study Of NKTR-214 In Subjects With Locally Advanced Or Metastatic Solid Tumor Malignancies

Recruiting
Phase of Trial: Phase I

Latest Information Update: 05 Jun 2017

At a glance

  • Drugs NKTR 214 (Primary)
  • Indications Malignant melanoma; Non-small cell lung cancer; Renal cell carcinoma; Solid tumours
  • Focus Adverse reactions; First in man
  • Acronyms EXCEL
  • Sponsors Nektar Therapeutics
  • Most Recent Events

    • 05 Jun 2017 Results published in a Nektar Therapeutics media release.
    • 02 Jun 2017 Results (n=26) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 20 Apr 2017 According to a Nekar Therapeutics media release, the company plans to review data from this trial at an Analyst and Investor Event to be hosted by the company during the 2017 American Society of Clinical Oncology (ASCO) Meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top